Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.

Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.

The direct-to-consumer telehealth company said the workforce reduction is unrelated to its weight-loss drug sector.

That overweight person you’re judging might not be able to control the amount they eat. For ten years, Joshua Bell was part ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

The large molecule injectable drugs market is anticipated to expand at a CAGR of ~9% during the forecast period. Key drivers ...

For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.

The outbreak occurred in a flock of 190 backyard poultry birds in the district of Birzgales, Paris-based WOAH said in a notice, citing Latvian authorities. Vera shares skyrocket as kidney disease drug ...

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

The retina is essential for visual function, and disruptions in its physiological balance can lead to severe visual impairments. Disorders like age-related ...

Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.